CureVac

CureVac AG is a biopharmaceutical company dedicated to the development of messenger ribonucleic acid therapies (mRNA Therapeutics). Headquartered in Thuringia, Germany, it has branches in Frankfurt and Boston, USA.CureVac AG is one of the global leaders in the field of mRNA drug research and development. In 2013, they collaborated with Johnson & Johnson to develop a new influenza vaccine; in 2015, they received investment from the Bill & Melinda Gates Foundation and, in the same year, partnered with the International AIDS Vaccine Initiative (IAVI) to develop an HIV vaccine; in 2017, they collaborated with Eli Lilly to develop a cancer vaccine.The COVID-19 vaccine developed by CureVac AG, located in Tübingen, has started clinical trials. The Paul Ehrlich Institute (PEI) announced approval for the company to conduct clinical trials of its vaccine on healthy volunteers. The first group of volunteers will receive the vaccine this month.The messenger mRNA that CureVac AG relies on for vaccine development can guide protein synthesis. After vaccination, human cells form immune cells capable of recognizing foreign antigen proteins.